Grant Life Sciences

Grant Life Sciences (“Grant”) receives a waiver from N.I.R. Group that allows Grant to pursue alternate financing 

LOS ANGELES, March 31, 2008—Grant Life Sciences (OTC Bulletin Board: GLIF) announced today it has received a waiver from The N.I.R. Group, LLC (“N.I.R. Group”), a Roslyn, N.Y.-based hedge fund that allows Grant to pursue alternate financing to pay down, in whole or in part, an existing financing debt to N.I.R.

“The Company has greatly appreciated NIR’s support over the last two years and these important developments related to N.I.R. Group will allow Grant to further advance its serum-based test for cervical cancer in the largest market in the world, China,” said Hun-Chi Lin, Ph.D., Grant’s President and Chief Scientist.

 Read More (PDF)

Chinese and U.S. patents issue to Grant Life Sciences for its blood test that detects cervical cancer LOS ANGELES, Jan. 22, 2008—Grant Life Sciences (OTC Bulletin Board: GLIF) announced today it has received notice from the China Patent Office that Patent No. ZLO38150247—‘PEPTIDES FROM THE E2, E6 and E7 PROTEINS OF HUMAN PAPILLOMAVIRUSES 16 AND 18 FOR DETECTING AND/OR DIAGNOSING CERVICAL AND OTHER CANCERS’—­has issued to the Company.  

In addition, the Company also announced that it has received notice from the U.S. Patent & Trademark Office that Patent No. 7,316,908—‘PEPTIDES FROM THE E2 PROTEINS OF HUMAN PAPILLOMAVIRUSES 16 AND 18 FOR DETECTING AND/OR DIAGNOSING CERVICAL AND OTHER HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS—has issued to the Company. 

“While we are excited by both of these events, in particular this action by the Chinese government clears a path for us to move forward confidently as we seek a China-based development-and-commercialization partner for our serum-based test for cervical cancer in the largest market in the world,” said Hun-Chi Lin, Ph.D., Grant’s President and Chief Scientist, “and we fully expect that this Chinese patent will help us realize our goal of a Chinese partner.”

Read More (PDF)

Grant Life Sciences in-licenses HPV DNA-based test from Alphagenics

“This agreement now makes us exclusive licensee of the Alphagenics HPV DNA-based test in China, a country in which there is a very high incidence, unfortunately, of cervical cancer.”

- Hun-Chi Lin, Ph.D., President and Chief Scientist, Grant Life Sciences 

LOS ANGELES, Nov. 13, 2007—Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has signed a final agreement with Alphagenics Diaco Biotechnologies S.r.l. (Italy) to exclusively in-license the manufacturing and marketing rights to Alphagenics’ molecular diagnostic test for human papillomaviruses (HPVs) in China and the United States and non-exclusively in all other countries. The Alphagenics HPV test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories.  Alphagenics’ HPV DNA test complements the HPV blood test that Grant has been developing to detect the presence of antibodies produced only by cancer-causing HPV types.  There are some 100 types of HPV; however, only about 7 to 15 HPV-types cause most cervical cancers. While a blood-based test to detect precancerous evidence and cancer of the cervix is still viewed by Grant Life Sciences as the preferred test-methodology to address the needs of the developing world, molecular (DNA) testing is currently the approved test protocol in both the U.S. and Europe to identify the presence of different subtypes of HPV in the cervix.  Read More (PDF)